CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 59 enrolled
Drug / intervention
TriMoxiVanc +3 moredrug
Likely dose
TriMoxiVanc 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02515045
NCT02515045Phase 4Completed
CompareCT.gov

Comparison of Dropless Prophylaxis After Routine Phacoemulsification to Standard Drops Regimen

Carolina Eyecare Physicians, LLC·interventional·Posted Aug 4, 2015·Updated Feb 23, 2018

In Brief

A Phase 4 clinical trial evaluating TriMoxiVanc, Moxifloxacin HCl 0.5%, and 2 other interventions for Cataract. Completed, enrolled 59 participants across 4 sites.

Detailed Summary

To compare the use of an injectable compound containing an antibiotic and an anti-inflammatory at time of cataract surgery to standard of care that is the use 3 different topical medications to prevent inflammation and infection after routine cataract surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
CollaboratorsScience in Vision

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 4, 2015
Enrollment StartJan 1, 2015
Primary CompletionMar 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.9 years ago

Interventions

TriMoxiVancdrug

triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.

Moxifloxacin HCl 0.5%drug

Antibiotic to be used 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.

Ilevrodrug

NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.

Prednisolone acetate 1%drug

Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.